High Sensitivity Label-Free Quantitative Method for Detecting Tumor Biomarkers in Human Serum by Optical Microfiber Couplers

Label-free optical fiber immunosensors have attracted widespread attention in recent decades due to their high sensitivity. However, nonspecific adsorption in serum has remained a critical bottleneck in existing label-free fiber optic biosensors, which hinders their widespread use in diagnostics. In addition, individual differences in clinical human serum (HS) negatively impact biosensing results. In this work, the modified serum preadsorption strategy was applied to reduce nonspecific adsorption by forming a saturated antifouling interface on an optical microfiber coupler (OMC). Furthermore, to reduce the effect of the differences between individual HS samples, we proposed a new method where Sigma HS was used as a wavelength shift reference due to being close to clinical serum compared to other serums. Sigma HS was used first to reduce the differences in immune sensors before performing a clinical sample test in which quantitative detection was achieved based on the independent calibration of several sensors with wide dynamic ranges via dissociation processes. The individual differences in 25% HS were corrected by 30% Sigma HS. As a proof of concept, the label-free OMC immune sensor demonstrates good sensitivity and specificity for the detection of carcinoembryonic antigen (CEA) in 25% Sigma HS at different concentrations. The detection limit of CEA reached as low as 34.6 fg/mL (0.475 fM). Additionally, label-free quantitative detection of CEA using this OMC immune sensor was verified experimentally according to the calibration line, and the results agree well with clinical examination detection. To our knowledge, it is the first study to employ an OMC immune sensor in point-of-care label-free quantitative detection for clinical HS.

Functional Micro-/Nanomaterials for Multiplexed Biodetection

When analyzing biological phenomena and processes, multiplexed biodetection has many advantages over single-factor biodetection and is highly relevant to both human health issues and advancements in the life sciences. However, many key problems with current multiplexed biodetection strategies remain unresolved. Herein, the main issues are analyzed and summarized: 1) generating sufficient signal to label targets, 2) improving the signal-to-noise ratio to ensure total detection sensitivity, and 3) simplifying the detection process to reduce the time and labor costs of multiple target detection. Then, available solutions made possible by designing and controlling the properties of micro- and nanomaterials are introduced. The aim is to emphasize the role that micro-/nanomaterials can play in the improvement of multiplexed biodetection strategies. Through analyzing existing problems, introducing state-of-the-art developments regarding relevant materials, and discussing future directions of the field, it is hopeful to help promote necessary developments in multiplexed biodetection and associated scientific research.

Current and future bioanalytical approaches for stroke assessment

Efforts are underway to develop novel platforms for stroke diagnosis to meet the criteria for effective treatment within the narrow time window mandated by the FDA-approved therapeutic (<3 h). Blood-based biomarkers could be used for rapid stroke diagnosis and coupled with new analytical tools, could serve as an attractive platform for managing stroke-related diseases. In this review, we will discuss the physiological processes associated with stroke and current diagnostic tools as well as their associated shortcomings. We will then review information on blood-based biomarkers and various detection technologies. In particular, point of care testing that permits small blood volumes required for the analysis and rapid turn-around time measurements of multiple markers will be presented.